410. Impact of Pediatric Antifungal Adverse Drug Reactions on Prescribing Practices
Session: Poster Abstract Session: Fungal Disease: Management and Outcomes
Thursday, October 4, 2018
Room: S Poster Hall
  • Goldman IDSA 2018 ADR antifungals FINAL [Compatibility Mode].pdf (125.7 kB)
  • Background: While antibiotics frequently cause adverse drug reactions (ADR), the rate of antifungal (AF) ADR is unknown. The mechanisms of AF ADR and cross-reactivity among a drug class (i.e. azoles) are poorly understood. Given the use of AF therapy is on the rise, it is important to better understand the prevalence of AF ADR and how these reactions influence prescribing.

    Methods: Thirty-two hospitals participated in a quarterly pediatric point prevalence survey that documented details on all admitted patients 0-17 years receiving any systemic antimicrobials, including drug, dose, and documented history of an antimicrobial ADR between 6/2016-12/2017. Patients who were recorded as receiving at least one systemic AF were included. A comparison of AF prescribing practices between those with and without an AF ADR was performed.

    Results: Among 13179 total patients, 2213 AF were prescribed to 2101 unique patients. The most common indications for AF included prophylaxis (64%), fever with neutropenia (4%), neonatal sepsis (3%), and catheter related bloodstream infection (3%).  The prevalence of patients with any documented AF ADR was 2.9%. Amphotericin was most commonly associated with an ADR. Fluconazole was the most commonly prescribed AF in those with no ADR (49%) as compared to those with an AF ADR (13%; p <.05). Patients with an amphotericin ADR were more likely to receive voriconazole (29%) as compared to those without (15%; p<.05). Interestingly, posaconazole use was highest in those with an azole ADR (22%) as compared to those with no azole ADR (4%; p < .05). Echinocandin ADR were infrequent, and those with a reported ADR still received an echinocandin 62% of the time.

    Conclusion: Significant differences in antifungal prescribing exists based on ADR status. More work is needed to be able to effectively classify AF ADR, determine safe prescribing practices in those with an AF ADR, and evaluate outcomes associated with AF ADR status.  


    Jennifer Goldman, MD, MS1, Jason Newland, MD, MEd, FPIDS2, Diana Yu, PharmD, BCPS-AQ ID3, Karisma Patel, PharmD, BCPPS4, Alaina Burns, PharmD1, Ann Wirtz, PharmD1 and Brian R. Lee, MPH, PhD5,6, (1)Children's Mercy Kansas City, Kansas City, MO, (2)Washington University S, Kansas City, MO, (3)Doernbecher Children's Hospital, Portland, OR, (4)Children's Health, Dallas, TX, (5)Health Outcomes, Children's Mercy Kansas City and University of Missouri-Kansas City SOM, Kansas City, MO, (6)Children's Mercy Hospital, Kansas City, MO


    J. Goldman, None

    J. Newland, None

    D. Yu, None

    K. Patel, None

    A. Burns, None

    A. Wirtz, None

    B. R. Lee, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.